Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Decitabine Followed by Clofarabine, Idarubicin, and Cytarabine in Acute Leukemia

Phase 1

Completed

Conditions: Leukemia

Interventions: Drug: Decitabine
Drug: Idarubicin
Drug: Cytarabine
Drug: Clofarabine

First Posted Date: 2013-02-20

Last Posted Date: 2019-05-30

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 65

Registration Number: NCT01794702

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Intervention for Symptom Burden During Maintenance Therapy for Multiple Myeloma

Phase 2

Completed

Conditions: Myeloma

Interventions: Other: Placebo
Drug: Minocycline
Behavioral: Questionnaires

First Posted Date: 2013-02-15

Last Posted Date: 2021-11-24

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 88

Registration Number: NCT01793051

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Ask Advise Connect (AAC) Harris Heath CPRIT

Active, not recruiting

Conditions: Tobacco Use Cessation

Interventions: Behavioral: Smoking Cessation Training
Behavioral: Quitline-Delivered Proactive Telephone Counseling
Behavioral: Qualitative Interviews Concerning the Implementation of AAC
Behavioral: Follow-Up Phone Call

First Posted Date: 2013-02-11

Last Posted Date: 2019-05-28

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 5212

Registration Number: NCT01788787

Locations: 🇺🇸
Harris Health System, Houston, Texas, United States

Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm

Phase 2

Recruiting

Conditions: Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable
Myelofibrosis Transformation in Essential Thrombocythemia
Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase
Primary Myelofibrosis

Interventions: Drug: Azacitidine
Other: Laboratory Biomarker Analysis
Drug: Ruxolitinib Phosphate

First Posted Date: 2013-02-08

Last Posted Date: 2025-06-03

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 125

Registration Number: NCT01787487

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery

Phase 1

Active, not recruiting

Conditions: Unresectable Solid Neoplasm
Metastatic Malignant Solid Neoplasm
Stage IV Colorectal Cancer AJCC v7
Stage IVA Colorectal Cancer AJCC v7
BRAF NP_004324.2:p.V600X
Stage IVB Colorectal Cancer AJCC v7
KRAS wt Allele

Interventions: Biological: Cetuximab
Drug: Irinotecan Hydrochloride
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Drug: Vemurafenib

First Posted Date: 2013-02-08

Last Posted Date: 2025-03-30

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 33

Registration Number: NCT01787500

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Donor Natural Killer Cells in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Phase 1

Completed

Conditions: Refractory Acute Myeloid Leukemia
Recurrent Adult Acute Myeloid Leukemia

Interventions: Drug: Cytarabine
Biological: Filgrastim
Biological: Filgrastim-sndz
Drug: Fludarabine Phosphate
Other: Laboratory Biomarker Analysis
Biological: Membrane-bound Interleukin-21-Expanded Haploidentical Natural Killer Cells

First Posted Date: 2013-02-08

Last Posted Date: 2021-06-21

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 30

Registration Number: NCT01787474

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer

Phase 2

Active, not recruiting

Conditions: Recurrent Prostate Carcinoma
Prostate Adenocarcinoma

Interventions: Drug: Bicalutamide
Drug: Abiraterone Acetate
Drug: Degarelix
Drug: Flutamide
Drug: Goserelin Acetate
Drug: Leuprolide Acetate
Drug: Nilutamide
Drug: Prednisone

First Posted Date: 2013-02-07

Last Posted Date: 2025-02-14

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 310

Registration Number: NCT01786265

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Decitabine for Older or Unfit Patients With Acute Myeloid Leukemia (AML)

Phase 2

Completed

Conditions: Leukemia

Interventions: Drug: Decitabine

First Posted Date: 2013-02-07

Last Posted Date: 2020-04-15

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 74

Registration Number: NCT01786343

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Ph II Cilengitide Plus Bevacizumab for Recurrent Glioblastoma (GBM)

Phase 2

Withdrawn

Conditions: Glioblastoma

Interventions: Drug: Cilengitide
Drug: Bevacizumab
Behavioral: Questionnaire

First Posted Date: 2013-02-04

Last Posted Date: 2018-01-19

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT01782976

Carfilzomib in Refractory Renal Cell Carcinoma (RCC)

Phase 2

Completed

Conditions: Kidney Cancer

Interventions: Drug: Carfilzomib

First Posted Date: 2013-01-25

Last Posted Date: 2020-03-04

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 10

Registration Number: NCT01775930

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy